1887

Chapter 29 : Epidemiology and Treatment Options for Select Community-Acquired and Nosocomial Antibiotic-Resistant Pathogens

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in
Zoomout

Epidemiology and Treatment Options for Select Community-Acquired and Nosocomial Antibiotic-Resistant Pathogens, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817572/9781555813291_Chap29-1.gif /docserver/preview/fulltext/10.1128/9781555817572/9781555813291_Chap29-2.gif

Abstract:

This chapter outlines the impact of antimicrobial resistance by describing the epidemiology of select antimicrobial-resistant pathogens and the difficulties associated with treatment of infections caused by these organisms. It discusses antimicrobial treatment options for infections caused by resistant enterococci, , , and . The arrival of vancomycin-resistant enterococci (VRE) is often attributed to the overuse of vancomycin, which has increased about 100-fold in the last 20 years, predominantly to treat methicillin-resistant (MRSA), enterococcal, and infections. The most important risk factors for VRE colonization and infection include severe underlying disease, extended hospital stay, and previous antimicrobial exposure. In the absence of literature supporting the use of one agent versus another, linezolid should be used as first line therapy for VRE infections, because it can cover both and . No population or geographical region is immune or isolated from the risk of infection with the primary cause of tuberculosis (TB) . Vaccine candidates that have been developed so far include recombinant Bacillus Calmette-Guérin; attenuated ; subunit and pooled subunit vaccines; fusion polyproteins; and DNA vaccines.

Citation: Gustafson J, Goldman J. 2005. Epidemiology and Treatment Options for Select Community-Acquired and Nosocomial Antibiotic-Resistant Pathogens, p 387-400. In White D, Alekshun M, McDermott P (ed), Frontiers in Antimicrobial Resistance. ASM Press, Washington, DC. doi: 10.1128/9781555817572.ch29

Key Concept Ranking

Infectious Diseases
0.49456513
Pneumococcal Conjugate Vaccine
0.48766348
Acute Otitis Media
0.46548012
Urinary Tract Infections
0.41136256
0.49456513
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555817572.chap29
1. Alland, D.,, G. E. Kalkut,, A. R. Moss,, R. A. McAdam,, J. A. Hahn,, W. Bosworth,, E. Drucker,, and B. R. Bloom. 1994. Transmission of tuberculosis in New York City. An analysis of DNA fingerprinting and conventional epidemiologic methods. N. Engl. J. Med. 330: 1710 1716.
2. Almeida, D.,, C. Rodriques,, Z. F. Udwadia,, A. Lalvani,, G. D. Gothi,, P. Mehta,, and A. Mehta. 2003. Incidence of multidrugresistant tuberculosis in urban and rural India and implications for prevention. Clin. Infect. Dis. 36: 152 154.
3.American Academy of Pediatrics Committee on Infectious Diseases. 1997. Therapy for children with invasive pneumococcal infections. Pediatrics 99: 289299.
4.American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media. 2004. Diagnosis and management of acute otitis media. Pediatrics 113: 14511465.
5. Andries, K. P. Verhasselt, J. Guillemont, H. W. H. Göhlman, J. M. Neefs, H. Winkler, J. Van Gestal, P. Timmerman, M. Zhu, E. Lee, P. Williams, D. de Chaffoy, E. Huitric, S. Hoffner, E. Cambau, C. Truffot-Pernot, N. Lounis, and V. Jarlier. 2005. A diarylquinolone drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223 227.
6. Baggett, H. C.,, T. W. Hennessy,, K. Rudolph,, D. Bruden,, A. Reasonover,, A. Parkinson,, R. Sparks,, R. M. Donlan,, P. Martinez,, K. Mongkolrattanothai,, and J. C. Butler. 2004. Community- onset methicillin-resistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska. J. Infect. Dis. 189: 1565 73.
7. Bartlett, J. G.,, and L. M. Mundy. 1995. Community-acquired pneumonia. N. Engl. J. Med. 333: 1618 1624.
8. Bartlett, J. G.,, S. F. Dowell,, L. A. Mandell,, T. M. File, Jr., D. M. Musher, and M. J. Fine. 2000. Pactice guidelines for the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 31: 347 382.
9. Barnes, P. F.,, and M. D. Cave. 2003. Molecular epidemiology of tuberculosis. New Engl. J. Med. 349: 1149 1156.
10. Bassetti, M.,, P. A. Farrel,, D. A. Callan,, J. E. Topal,, and L. M. Dembry. 2003. Emergence of linezolid-resistant Enterococcus faecium during treatment of enterococcal infections. Int. J. Antimicrob. Agents. 21: 593 594.
11. Benton, B. M.,, J. P. Zhang,, S. Bond,, C. Pope,, T. Christian,, L. Lee,, K. M. Winterberg,, M. B. Schmid,, and J. M. Buysse. 2004. Large-scale identification of genes required for full virulence of Staphylococcus aureus. J. Bacteriol. 186: 8478 8489.
12. Bifani, P. J.,, B. Mathema,, N. E. Kurepina,, and B. N. Kreiswirth. 2002. Global dissemination of the Mycobacterium tuberculosis W-Beijing family strains. Trends Microbiol. 10: 45 52.
13. Blumberg, H. M.,, W. J. Burman,, R. E. Chaisson,, C. L. Daley,, S. C. Etkind,, L. N. Friedman,, P. Fujiwara,, M. Grzemska,, P. C. Hopewell,, M. D. Iseman,, R. M. Jasmer,, V. Koppaka,, R. I. Menzies,, R. J. O’Brien,, R. R. Reves,, L. B. Reichman,, P. M. Simone,, J. R. Starke,, A. A. Vernon; AmericanThoracicSociety,Centers for Disease Control and Prevention and the Infectious Diseases Society. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167: 603 662.
14. Bouvet, E.,, E. Casalino,, G. Mandoza-Sassi,, S. Lariven,, E. Vallée,, M. Pernet,, S. Gottot,, and F. A. Vachon. 1993. A nosocomial outbreak of multidrug-resistant Mycobacterium bovis among HIV-infected patients, a case-control study. AIDS 7: 1453 1460.
15. Bryan, C. S.,, R. Talwani,, and M. S. Stinson. 1997. Penicillin dosing for pneumococcal pneumonia. Chest 112: 1657 1664.
16. Bucher, H. C.,, L. E. Griffith,, G. H. Guyatt,, P. Sudre,, M. Naef,, P. Sendi,, and M. Battegay 1999. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 13: 501 507.
17.Centers for Disease Control and Prevention. 1997. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly. Rep. 46: 124.
18. Centers for Disease Control and Prevention. 1997. Reduced susceptibility of Staphylococcus aureus to vancomycin—Japan, 1996. Morb. Mortal. Wkly. Rep. 46: 624626.
19. Centers for Disease Control and Prevention. 1997. National Nosocomial Infections Surveillance (NNIS) System report: data summary from October 1986-April 1997, issued May 1997. Am. J. Infect. Control 25: 477487.
20. Centers for Disease Control and Prevention. 1999. National Nosocomial Infections Surveillance (NNIS) System report: data summary from January 1990-May 1999, issued June 1999. Am. J. Infect. Control 27: 520532.
21.Centers for Disease Control and Prevention. 2000. Public health focus:surveillance, prevention and control of nosocomial infections. Morb. Mortal. Weekly Rep. 41: 783787.
22. Centers for Disease Control and Prevention. 2002. Staphylococcus aureus resistant to vancomycin—United States, 2002. Morb. Mortal. Wkly. Rep. 51: 565576.
23. Centers for Disease Control and Prevention. 2002. Campaign to prevent antimicrobial resistance in healthcare settings. Available at: http://www.cdc.gov/drugresistance/healthcare/default. htm.
24.Centers for Disease Control and Prevention. 2003. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infections—United States. Morb. Mortal. Wkly. Rep. 52: 735739.
25. Centers for Disease Control and Prevention. 2004. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha—California, 2002-2003. Morb. Mortal. Wkly. Rep. 53: 683686.
26. Centers for Disease Control and Prevention. 2004. Trends in tuberculosis—United States, 1998-2003. Morb. Mortal. Wkly. Rep. 53: 209214.
27. Cetinkaya, Y., Falk, P., and C. G. Mayhall. 2000. Vancomycinresistant enterococci. Clin. Microbiol. Rev. 13: 686 707.
28.Chaves F., J. Garcia-Martinez, S. de Miguel, and J. R. Otero. 2003. Molecular characterization of resistance to mupirocin in methicillin-susceptible and -resistant isolates of Staphylococcus aureus from nasal samples. Antimicrob. Agents Chemother. 47: 15891597.
29. Cottagnoud, P.,, M. Pfister,, F. Acosta,, M. Cottagnoud,, L. Flatz,, F. Kühn, H-P. Müller, and A. Stucki. 2004. Daptomycin is highly efficacious against penicillin-resistant and penicillinand quinolone-resistant pneumococci in experimental meningitis. Antimicrob. Agents Chemother. 48: 3928 3933.
30. D’Agata, E. M. C.,, S. Gautam,, W. K. Green,, and Y. W. Tang. 2002. High rate of false-negative results of rectal swab culture method in detection of gastrointestinal colonization with vancomycin-resistant enterococci. Clin. Infect. Dis. 34: 167 172.
31. David, H. L. 1970. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl. Microbiol. 20: 810 814.
32. de Gans, J.,, and D. van de Beek. 2002. Dexamethasone in adults with bacterial meningitis. N. Engl. J. Med. 347: 1549 1556.
33. DeLisle, S.,, and T. M. Perle. 2003. Vancomycin-resistant enterococci: A road map on how to prevent the emergence and transmission of antimicrobial resistance. Chest 123: 504S 518S.
34. Dodge, R. A.,, J. S. Daly,, R. Davaro,, and R. H. Glew. 1996. High dose ampicillin plus streptomycin for treatment of a patient with a severe infection due to multi-resistant enterococci. Clin. Infect. Dis. 25: 1269 1270.
35. Doern, G. V.,, A. B. Brueggemann,, M. Blocker,, M. Dunne,, H. P. Holley, Jr., K. S. Kehl, J. Duval, K. Kugler, S. Putnam, A. Rauch, and M. A. Pfaller. 1998. Clonal relationships among high-level penicillin-resistant Streptococcus pneumoniae in the United States. Clin. Infect. Dis. 27: 757 761.
36. Dowell, S. F.,, J. C. Butler,, G. S. Giebink,, M. R. Jacobs,, D. Jernigan,, D. M. Musher,, A. Rakowsky,, and B. Schwartz. 1999. Acute otitis media: management and surveillance in an era of pneumococcal resistance-a report from the Drugresistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr. Infect. Dis. 18: 1 9.
37. Dowzicky, M.,, G. H. Talbot,, C. Feger,, P. Prokocimer,, J. Etienne,, and R. Leclercq. 2000. Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid) during a worldwide clinical program. Diagn. Microbiol. Infect. Dis. 37: 57 62.
38. Dye, C.,, M. A. Espinal,, C. J. Watt,, C. Mbiaga,, and B. G. Williams. 2002. Worldwide incidence of multidrug-resistant tuberculosis. J. Infect. Dis. 185: 1197 1202.
39. El-khoury, J.,, and J. A. Fishman. 2003. Linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections in solid organ transplants: report of a multicenter compassionate- use trial. Transpl. Infect. Dis. 5: 121 125.
40. Enright, M. C.,, D. A. Robinson,, G. Randle,, E. J. Feil,, H. Grundmann,, and B. G. Spratt. 2002. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc. Natl. Acad. Sci. USA 99: 7687 7692.
41. Feikin, D.,, A. Schuchat,, M. Kolczak,, N. L. Barrett,, L. H. Harrison,, L. Lefkowitz,, A. McGeer,, M. M. Farley,, D. J. Vugia,, C. Lexau,, K. R. Stefonek,, J. E. Patterson,, and J. H. Jorgensen. 2000. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am. J. Public Health. 90: 223 229.
42. Finney, M. S.,, C. W. Crank,, and J. Segreti. 2004. Daptomycin for treatment of drug-resistant Gram-positive bacteremia and infective endocarditis. 42nd Infect. Dis. Soc. Amer. Meeting abstracts, Washington D.C.
43. Fridkin, S. K.,, J. R. Edwards,, J. M. Courval,, H. Hill,, F. C. Tenover,, R. Lawton,, R. P. Gaynes,, and J. E. McGowan Jr. Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project and the National Nosocomial Infections Surveillance (NNIS) System Hospitals. 2001. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin- resistant enterococci in 126 U.S. adult intensive care units. Ann. Intern. Med. 135: 175 183.
44. Friedland, I. R,, S. Shelton, M. Paris, S. Rinderknecht, S. Ehrett, K. Krisher, and G. H. McCracken. 1993. Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr. Infect. Dis. J. 12: 196 200.
45. Friedland, I. R. 1995. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr. Infect. Dis. 14: 885 890.
46. Gillespie, S. H. 2002. Evolution of resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob. Agents Chemother. 46: 267 274.
47. Gonzalez, B. E.,, G. Martinez-Aguilar,, K. G. Hulten,, W. A. Hammerman,, J. Coss-Bu,, A. Avalos-Mishaan,, E. O. Mason, Jr., and S. L. Kaplan. 2005. Severe staphylococcal sepsis in adolescents in the era of community-acquired methicillin-resistant Staphylococcus aureus. Pediatrics 115: 642 648.
48. Gosling, R. D.,, L. O. Uiso,, N. E. Sam,, E. Bongard,, E. G. Kanduma,, M. Nyindo,, R. W. Morris,, and S. H. Gillespie. 2003. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 168: 1342 1345.
49. Grimwood, K.,, P. Anderson,, V. Anderson,, L. Tan,, and T. Nolan T. 2000. Twelve year outcomes following bacterial meningitis: further evidence for persisting effects. Arch. Dis. Child. 83: 111 116.
50. Hageman, J. C.,, D. A. Pegues,, C. Jepson,, R. L. Bell,, M. Guinan,, K. W. Ward,, M. D. Cohen,, J. A. Hindler,, F. C. Tenover,, S. K. McAllister,, M. E. Kellum,, and S. K. Fridkin. 2001. Vancomycin-intermediate Staphylococcus aureus in a home health-care patient. Emerg. Infect. Dis. 7: 1023 1025.
51. Hansel, N. N.,, B. Merriman,, E. F. Haponik,, and G. B. Diette. 2004. Hospitalizations for tuberculosis in the United States in 2000: predictors of in-hospital mortality. Chest 126: 1079 1086.
52. Harbarth, S.,, S. Cosgrove,, and Y. Carmeli. 2002. Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 46: 1619 1628.
53. Heffelfinger, J. D.,, S. F. Dowell,, J. H. Jorgensen,, K. P. Klugman,, L. R. Mabry,, D. M. Musher,, J. F. Plouffe,, A. Rakowsky,, A. Schuchat,, and C. G. Whitney. 2000. Management of community- acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch. Intern. Med. 160: 1399 1408.
54. Howden, B. P.,, P. B. Ward,, P. G. Charles,, T. M. Korman,, A. Bak,, J. Hurley,, P. D. Johnson,, A. J. Morris,, B. C. Mayall,, and M. L. Grayson. 2004. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 38: 521 528.
55. Howe, R. A.,, M. Robson,, A. Oakhill,, J. M. Cornish,, and M. R. Millar. 1997. Successful use of tetracycline as therapy of an immunocompromised patient with septicaemia caused by a vancomycin-resistant enterococcus. J. Antimicrob. Chemother. 40: 144 145.
56. Ing, M. B.,, L. M. Baddour,, and A. S. Bayer,. 1997. Bacteremia and infective endocarditis: pathogenesis, diagnosis, and complications, p. 331 354. In K. B. Crossley, and G. L. Archer (ed.), The Staphylococci in Human Disease. Churchill Livingstone, New York, N.Y.
57. Ioanas, M.,, and H. Lode. 2004. Linezolid in VAP by MRSA: a better choice. Intensive Care Med. 30: 343 346.
58. Izzo, A. A.,, L. Brandt,, T. Lasco,, A.-P. Kipnis,, I. Orme. NIH pre-clinical screening program: Overview and current status. Tuberculosis, in press.
59. Jacobs, M. R.,, H. J. Koornhof,, R. M. Robins-Browne,, C. M. Stevenson,, Z. A. Vermaak,, I. Freiman,, G. B. Miller,, M. A. Witcomb,, M. Isaacson,, J. L. Ward,, and R. Austrian. 1978. Emergence of multiply resistant penumococci. N. Engl. J. Med. 299: 735 740.
60. Jones, M. E.,, D. C. Draghi,, C. Thornsberry,, J. A. Karlowsky,, D. F. Sahm,, and R. P. Wenzel. 2004. Emerging resistance among bacterial pathogens in the intensive care unit—a European and North American Surveillance study (2000-2002). Ann. Clin. Microbiol. Antimicrob. 3: 14 24.
61. Kaplan, S. L. 2002. Management of pneumococcal meningitis. Pediatr. Infect. Dis. J. 21: 589 591.
62. Kauffman, C. A. 2003. Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections. J. Antimicrob. Chemother. 51: iii23 iii30.
63. Kennedy, N.,, R. Fox,, G. M. Kisyombe,, A. O. Saruni,, L. O. Uiso,, A. R. Ramsay,, F. I. Ngowi,, and S. H. Gillespie. 1993. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am. Rev. Respir. Dis. 148: 1547 1551.
64. Kirst, H. A.,, D. G. Thompson,, and T. I. Nicas. 1998. Historical yearly usage of vancomycin. Antimicrob. Agents Chemother. 42: 1303 1304.
65. Klugman, K. P. 2002. The successful clone: the vector of dissemination of resistance in Streptococcus penumoniae. J. Antimicrob. Chemother. 50: S1 S5.
66. Kluytmans, J.,, A. van Belkum,, and H. Verbrugh. 1997. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin. Microbiol. Rev. 10: 505 520.
67. Kokai-Kun, J. F.,, S. M. Walsh,, T. Chanturiya,, and J. J. Mond. 2003. Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob. Agents Chemother. 47: 1589 1597.
68. Kuhn, F.,, M. Cottagnoud,, F. Acosta,, L. Flatz,, J. Entenza,, and P. Cottonwood. 2003. Cefotaxime acts synergistically with levofloxacin in experimental meningitis due to penicillinresistant pneumococci and prevents selection of levofloxacinresistant mutants in vivo. Antimicrob. Agents Chemother. 47: 2487 2491.
69. Kupronis, B.A.,, C. L. Richards,, C. G. Whitney; Active Bacterial Core Surveillance Team. 2003. Invasive pneumococcal disease in older adults residing in long-term care facilities and in the community. J. Am. Geriatr. Soc. 51: 1520 1525.
70. Lautenbach, E.,, C. V. Gould,, L. A. LaRosa,, A. M. Marr,, I. Nachamkin,, W. B. Bilker,, and N. O. Fishman. 2004. Emergence of resistance to chloramphenicol among vancomycinresistant enterococcal (VRE) blood stream isolates. Int. J. Antimicrob. Agents. 23: 200 203.
71. Lave, J. R.,, C. J. Lin,, M. J. Fine,, and P. Hughes-Cromwick. 1999. Cost of treating patients with community acquired pneumonia. Sem. Resp. Crit. Care Med. 20: 189 197.
72. Leggiadro, R. J. 1994. Penicillin- and cephalosporin-resistant Streptococcus pneumoniae: an emerging microbial threat. Pediatrics 93: 500 503.
73. Levy, S. B. 2002. The 2000 Garrod Lecture: Factors impacting on the problem of antibiotic resistance. J. Antimicrob. Chemo. 49: 25 30.
74. Levy, S. B.,, and B. Marshall. 2004. Antibacterial resistance worldwide: causes challenges and responses. Nat. Med. 10: S122 S129.
75. Lewis, J. S. II., and J. H. Jorgensen. 2005. Inducible clindamycin resistance in staphylococci: should clinicians and microbiologists be concerned. Clin. Infect. Dis. 40: 280 285.
76. Linden, P. K.,, A. W. Pasculle,, D. McDevitt,, and D. J. Kramer. 1997. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort. J. Antimicrob. Chemother. 39: 145 151.
77. Linden, P. K.,, R. C. Moellering,, R. A. Wood,, S. J. Rehm,, J. Flaherty,, F. Bompart,, G. H. Talbot; Synercid Emergency-Use Study Group. 2001. Treatment of vancomycin-resistant Enterococcus faecium with quinupristin-dalfopristin. Clin. Infect. Dis. 33: 1816 1823.
78. Lowy, F. D. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339: 520 532.
79. Lynch, J. P., 3rd. 2000. Community-acquired pneumonia: risk factors and specific causes. J. Resp. Dis. 21: 457 468.
80. Mandell, L. A.,, J. G. Bartlett,, S. F. Dowell,, T. M. File Jr., D. M. Musher, C. Whitney and Infectious Diseases Society of America. 2003. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis. 37: 1405 1433.
81. Markowitz, N.,, E. L. Quinn,, and L. D. Saravolatz. 1992. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann. Int. Med. 117(5): 390 398.
82. Martinez-Aguilar G, A. Avalos-Mishaan,, K. Hulten,, W. Hammerman,, E. O. Mason, Jr.,, and S. L. Kaplan. 2004. Community- acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr. Infect. Dis. J. 23: 701 706.
83. Mascini, E. M.,, K. P. Jalink,, T. E. M. Kamp-Hopmans,, H. E. M. Blok,, J. Verhoef,, M. J. M. Bonten,, and A. Troelstra. 2003. Acquisition and duration of vancomycin-resistant enterococcal carriage in relation to strain type. J. Clin. Microbiol. 41: 5377 5383.
84. May, J.,, K. Shannon,, A. King,, and G. French. 1998. Glycopeptide tolerance in Staphylococcus aureus. J. Antimicrob. Chemother. 42: 189 197.
85. McCollum, M.,, D. C. Rhew,, and S. Parodi. 2003. Cost analysis of switching from i.v. to p.o. linezolid for the management of methicillin-resistant Staphylococcus species. Clin. Ther. 25: 3173 3179.
86. McGee, L.,, L. McDougal,, J. Zhou,, B. G. Spratt,, F. C. Tenover,, R. George,, R. Hakenbeck,, W. Hryniewicz,, J. C. Lefevre,, A. Tomasz,, and K. P. Klugman. 2001. Nomenclature of major antimicrobial- resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. J. Clin. Microbiol. 39: 2565 2571.
87. Medical Research Council. 1950. Treatment of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid. Br. Med. J. 2: 10731085.
88. Mekonen, E. T.,, G. A. Noskin,, D. M. Hacek,, and L. R. Peterson. 1995. Successful treatment of persistent bacteremia due to vancomycin-resistant, ampicillin-resistant Enterococcus faecium. Microb. Drug Resist. 1: 249 253.
89. Moellering, R. C. 2003. Linezolid: the first oxazolidinone antimicrobial. Ann. Intern. Med. 138: 135 142.
90. Montecalvo, M. A. 2003. Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients. J. Antimicrob. Chemother. 51: iii31 iii35.
91. Mulholland, E. K. 1997. A report prepared for the Scientific Advisory Group of Experts, Global Programme for Vaccines and Immunization. Geneva, World Health Organization.
92. Mylotte, J. M.,, C. McDermott,, and J. A. Spooner. 1987. Prospective study of 114 consecutive episodes of Staphylococcus aureus infections. Rev. Infect. Dis. 9: 891 907.
93. Naimi, T. S.,, K. H. LeDell,, K. Como-Sabetti,, S. M. Borchardt,, D. J. Boxrud,, J. Etienne,, S. K. Johnson,, F. Vandenesch,, S. Fridkin,, C. O’Boyle,, R. N. Danila,, and R. Lynfield. 2003. Comparison of community- and health care-associated methicillin- resistant Staphylococcus aureus infection. JAMA 290: 2976 2984.
94. Niederman, M. S.,, J. S. McCombs,, A. N. Unger,, A. Kumar,, R. Popovian. 1998. The cost of treating community-acquired pneumonia. Clin. Ther. 20: 820 837.
95. Niederman, M. S.,, L. A. Mandell,, A. Anzueto,, J. B. Bass,, W. A. Broughton,, G. D. Campbell,, N. Dean,, T. File,, M. J. Fine,, P. A. Gross,, F. Martinez,, T. J. Marrie,, J. F. Plouffe,, J. Ramirez,, G. A. Sarosi,, A. Torres,, R. Wilson,, V. L. Yu, and American Thoracic Society. 2001. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 163: 1730 1754.
96. O’Brien, F. G.,, T. T. Lim,, F. N. Chong,, G. W. Coombs,, M. C. Enright,, D. A. Robinson,, A. Monk,, B. Said-Salim,, B. N. Kreiswirth,, and W. B. Grubb. 2004. Diversity among community isolates of methicillin-resistant Staphylococcus aureus in Australia. J. Clin. Microbiol. 42: 3185 3190.
97. Oliveira, D. C.,, A. Tomasz,, and H. de Lencastre. 2002. Secrets of success of a human pathogen: molecular evolution of pandemic clones of methicillin-resistant Staphylococcus aureus. Lancet Infect. Dis. 2: 180 189.
98. Pablos-Mendez, A.,, D. K. Gowda,, and T. R. Frieden. 2002. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational frame-work. Bull. World Health Org. 80: 489 500.
99. Pfeltz, R. F.,, and B. J. Wilkinson. 2004. The escalating challenge of vancomycin resistance in Staphylococcus aureus. Curr. Drug. Targ. Infect. Disord. 4: 1 22.
100. Pletz, M. W.,, A. De Roux,, A. Roth,, K. H. Neumann,, H. Mauch,, and H. Lode. 2004. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob. Agents Chemother. 48: 780 782.
101. Pletz, M. W.,, L. McGee,, J. Jorgensen,, B. Beall,, R. R. Facklam,, C. G. Whitney,, and K. P. Klugman. 2004. Levofloxacinresistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob. Agents Chemother. 48: 3491 3497.
102. Priest, D. H.,, L. F. Vossel Jr., E. A. Sherfy, D. P. Hoy and C. A. Haley. 2004. Use of intermittent rifampin and pyrazinamide for treatment of latent tuberculosis infection in a targeted testing program. Clin. Infect. Dis. 39: 1764 1771.
103. Raad, I.,, R. Hachem,, H. Hanna,, C. Afif,, C. Escalante,, H. Kantarjian,, and K. Rolston. 2004. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J. Antimicrob. Chemother. 53: 646 649.
104. Rajbhandary, S. S.,, S. M. Marks,, and N. N. Bock. 2004. Costs of patients hospitalized for multidrug-resistant tuberculosis/int. J. Tuberc. Lung Dis. 8: 1012 1016.
105. Rastogi, N., 2003. An introduction to mycobacterial taxonomy, structure, drug resistance, and pathogenesis, p. 89 115. In D. Dionisio (ed.), Textbook-Atlas of Intestinal Infections in AIDS. Springer-Verlag, Milan, Italy.
106. Ricaurte, J. C.,, H. W. Boucher,, G. S. Turett,, R. C. Moellering,, V. J. Labombardi,, and J. W. Kislak. 2001. Chloramphenicol treatment for vancomycin-resistant Enterococcus faecium bacteremia. Clin. Microbiol. Infect. 7: 17 21.
107. Rice, L. B. 2001. Emergence of vancomycin-resistant enterococci. Emerg. Infect. Dis. 7: 183 187.
108. Ridzon, R.,, C. G. Whitney,, M. T. McKenna,, J. P. Taylor,, S. H. Ashkar,, A. T. Nitta,, S. M. Harvey,, S. Valway,, C. Woodley,, R. Cooksey,, and I. M. Onorato. 1998. Risk factors for rifampin mono-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 157: 1881 1884.
109. Rieder, H. L.,, G. M. Cauthen,, A. B. Bloch,, C. H. Cole,, D. Holtzman,, D. E. Snider Jr., W. J. Bigler, and J. J. Witte. 1989. Tuberculosis and acquired immunodeficiency syndrome: Florida. Arch. Intern. Med. 149: 1268 1273.
110. Robinson, K. A.,, W. Baughman,, G. Rothrock,, N. L. Barrett,, M. Pass,, C. Lexau,, B. Damaske,, K. Stefonek,, B. Barnes,, J. Patterson,, E. R. Zell,, A. Schuchat,, C. G. Whitney; Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program Network. 2001. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. J. Am. Med. Assoc. 285: 1729 1735.
111. Rothermel, C. D. 2004. Penicillin and macrolide resistance in pneumococcal pneumonia: does in vitro resistance affect clinical outcomes? Clin. Infect. Dis. 38: S346 S349.
112. Rubin, R. J.,, C. A. Harrington,, A. Poon,, K. Dietrich,, J. A. Greene,, and A. Moiduddin. 1999. The economic impact of S taphylococcus aureus infection in New York City hospitals. Emerg. Infect. Dis. 5: 9 17.
113. Ruef, C. 2004. Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus. Infection 6: 315 327.
114. Schlievert, P. M. Personal communication.
115. Schrag, S. J.,, L. McGee,, C. G. Whitney,, B. Beall,, A. S. Craig,, M. E. Choate,, J. H. Jorgensen,, R. R. Facklam,, and K. P. Klugman, and Active Bacterial Core Surveillance Team. 2004. Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin. Antimicrob. Agents Chemother. 48: 3016 3023.
116. Schuchat, A.,, K. Robinson,, J. D. Wenger,, L. H. Harrison,, M. Farley,, A. L. Reingold,, L. Lefkowitz,, and B. A. Perkins. 1997. Bacterial Meningitis in the United States in 1995. Active Surveillance Team. N. Engl. J. Med. 337: 970 976.
117. Segreti, J.,, C. W. Crank,, and M. S. Finney. 2004. Daptomycin for treatment of drug-resistant Gram-positive bacteremia and infective endocarditis. IDSA meeting abstract, Washington D.C.
118. Shamputa, I. C.,, L. Rigouts,, L. A. Eyongeta,, N. A. El Aila,, A. van Deun,, A. H. Salim,, E. Willery,, C. Locht,, P. Supply,, and F. Portaels. 2004. Genotypic and phenotypic heterogeneity among Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients. J. Clin. Microbiol. 42: 5528 5536.
119. Shinefield, H.,, S. Black,, A. Fattom,, G. Horwith,, S. Rasgon,, J. Ordonez,, H. Yeoh,, D. Law,, J. B. Robbins,, R. Schneerson,, L. Muenz,, S. Fuller,, J. Johnson,, B. Fireman,, H. Alcorn,, and R. Naso. 2002. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. 346: 491 496.
120. Shlaes, D. M.,, D. N. Gerding,, J. F. John, Jr.,, W. A. Craig,, D. L. Bornstein,, R. A. Duncan,, M. R. Eckman,, W. E. Farrer,, W. H. Greene,, V. Lorian,, S. B. Levy,, J. E. McGowan, Jr.,, S. M. Paul,, J. Ruskin,, F. C. Tenover,, and C. Watanakunakorn. 1997. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America joint committee on the prevention of antimicrobial resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect. Control Hosp. Epidemiol. 18: 275 291.
121. Shorr, A. F.,, G. M. Sulsa,, and M. H. Kollef. 2004. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit. Care Med. 32: 137 145.
122. Sloas, M. M.,, F. F. Barrett,, P. J. Chesney,, B. K. English,, B. C. Hill,, F. C. Tenover,, and R. J. Leggiadro. 1992. Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr. Infect. Dis. J. 11: 662 666.
123. Smith, I. M.,, and A. B. Vickers. 1960. Natural history of 338 treated and untreated patients with staphylococcal septicemia. Lancet 1: 1318 1322.
124. Smith, T. L.,, M. L. Pearson,, K. R. Wilcox,, C. Cruz,, M. V. Lancaster,, B. Robinson-Dunn,, F. C. Tenover,, M. J. Zervos,, J. D. Band,, E. White,, and W. R. Jarvis. 1999. Emergence of vancomycin- resistance in Staphylococcus aureus. Glycopeptideintermediate Staphylococcus aureus working group. N. Engl. J. Med. 340: 493 501.
125. Sonnenberg, P.,, J. R. Glynn,, K. Fielding,, J. Murray,, P. Godfrey- Faussett,, and S. Shearer. 2005. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J. Infect. Dis. 191: 150 158.
126. Sterling, T. R. 2004. The WHO/IUATLD diagnostic algorithm for tuberculosis and emperic fluoroquinolone use: potential pitfalls. Int. J. Tuberc. Lung Dis. 8: 1396 1400.
127. The Stop TB Partnership. September 14th, 2004. TB/HIV: facts at a glance. Available at: http://www.stoptb.org/events/internationalaidsconference/ xv/assets/InfoPack/1GB.pdf.
128. Taylor, S. E.,, D. L Paterson,, and V. L. Yu. 1998. Treatment options for chronic prostatitis due to vancomycin-resistant Enterococcus faecium. Eur. J. Clin. Microbiol. Infect. Dis. 17: 798 800.
129. Tsiodras, S.,, H. S. Gold,, G. Sakoulas,, G. M. Eliopoulos,, C. Wennersten,, L. Venkataraman,, R. C. Moellering,, and M. J. Ferraro. 2001. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358: 207 208.
130. Tuberculosis Research Centre. 2002. Shortening short course chemotherapy: a randomised clinical trial for treatment of smear-positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Ind. J. Tuberc. 49: 2738.
131. Uttley, A. H. C.,, C. H. Collins,, J. Naidoo,, and R. C. George. 1988. Vancomycin-resistant enterococci. Lancet i: 57 58.
132. van Helden, P. D. 2003. The economic divide and tuberculosis. Tuberculosis is not just a medical problem, but also a problem of social inequality and poverty. EMBO Rep. 4: S24 S28.
133. Vankerckhoven, V.,, T. Van Autgaerden,, C. Vael,, C. Lammens,, S. Chapelle,, R. Rossi,, D. Jabes,, and H. Goossens. 2004. Development of a multiplex PCR for the detection of asa1, gelE, cylA, esp, and hyl genes in enterococci and survey for virulence determinants among European hospital isolates of Enterococcus faecium. J. Clin. Microbiol. 42: 4473 4479.
134. Vincent, J.,, V. J Quagliarello,, and W. M. Scheld. 1997. Treatment of bacterial meningitis. N. Engl. J. Med. 336: 708 716.
135. Wayne, L. G. 1994. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur. J. Clin. Microbiol. 13: 908 914.
136. Whitney, C.,, M. Farley,, J. Hadler,, L. Harrison,, C. Lexau,, A. Reingold,, L. Lefkowitz,, P. Cieslak,, M. Cetron,, E. Zell,, J. Jorgensen,, and A. Schuchat. 2000. Increasing prevalence of multidrug- resistant Streptococcus penumoniae in the United States. N. Engl. J. Med. 343: 1917 1924.
137. Winston, D. J.,, C. Emmanouilides,, A. Kroeber,, J. Hindler,, D. A. Bruckner,, M. C. Territo,, and R. W. Busuttil. 2000. Quinupristin-dalfopristin therapy for vancomycin-resistant Enterococcus faecium. Clin. Infect. Dis. 30: 790 797.
138.World Health Organization. 1997. W.H.O. report on the tuberculosis epidemic. World Health Organization, Geneva, Switzerland.
139. Wunderink, R. G.,, J. Rello,, and S. K. Cammarata. 2003. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124: 1789 1797.
140. Yu, V. L.,, C. C. Chiou,, C. Feldman,, A. Ortqvist,, J. Rello,, A. J. Morris,, L. M. Baddour,, C. M. Luna,, D. R. Snydman,, M. Ip,, W. C. Ko,, M. B. Chedid,, A. Andremont,, K. P. Klugman, and International Pneumococcal Study Group. 2003. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin. Infect. Dis. 37: 230 237.

Tables

Generic image for table
Table 1

Potential regimens for tuberculosis caused by drug-resistant strains of

Adapted from reference 13. Abbreviations: EMB, ethambutol; FQN, fluoroquinolone; IA, injectable agent; INH, isoniazid; PZA, pyrazinamide; RIF, rifampin; and SM, streptomycin.

Injectable agent may include aminoglycosides or the polypeptide capreomycin. Alternative agents: ethionamide, cycloserine, -aminosalicylic acid, clarithromycin, amoxicillin/clavulanate, and linezolid.

Citation: Gustafson J, Goldman J. 2005. Epidemiology and Treatment Options for Select Community-Acquired and Nosocomial Antibiotic-Resistant Pathogens, p 387-400. In White D, Alekshun M, McDermott P (ed), Frontiers in Antimicrobial Resistance. ASM Press, Washington, DC. doi: 10.1128/9781555817572.ch29

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error